Incyte Corporation: Hidradenitis Suppurativa trials

The registry lists 12 Hidradenitis Suppurativa studies with Incyte Corporation as lead sponsor. 3 are open to participants now and 4 have results posted.

Phase 1 1Phase 2 5Phase 3 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaRecruitingNCT07213973Phase 2
• Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
• Rollover Study for Participants Previously Enrolled in Clinical Trials of PovorcitinibRecruitingNCT06855498Phase 3
• Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaCompletedNCT05635838Phase 2Results posted
• To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT04476043Phase 2Results posted
• A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03607487Phase 2Results posted
• A Study of the Safety of INCB054707 in Participants With Hidradenitis SuppurativaCompletedNCT03569371Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Active, not recruitingNCT06959225Phase 3
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Active, not recruitingNCT06958211Phase 3
• A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06212999Phase 3
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05620836Phase 3
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT05620823Phase 3